The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs.

AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

Up to date, HANSIZHUANG has been approved by the National Medicinal Products Administration (NMPA) for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell ...